Richter did not disclose the purchase price.

The transaction requires the approval of the Romanian competition authority.

Richter CEO Gábor Orbán noted that the agreement follows the divestment of similar non-core businesses in Moldova in 2021 and "further increases strategic focus on core activities".

"The sustained protection of high margins achieved by our highly specialized pharmaceutical business segment is of paramount importance to Richter management," he added.